Division of General Internal Medicine

Division of General Internal Medicine
faculty photo

Yu-Ning Wong, MD MSCE

Adjunct Assistant Professor of Medicine
Department: Medicine

Contact information
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Office: 215-728-2429
Fax: 215-728-3639
Education:
BA
University of Virginia, 1995.
MD
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 1999.
MS (Clinical Epidemiology)
University of Pennsylvania, 2006.
Post-Graduate Training
Intern & Resident, Internal Medicine, Thomas Jefferson University Hospital, 1999-2002.
Fellow, Hematology and Medical Oncology, Temple University Hospital and Fox Chase Cancer Center, 2002-2005.
Certifications
American Board of Internal Medicine, 2002.
American Board of Internal Medicine, Medical Oncology, 2005.
American Board of Internal Medicine, Hematology, 2006.
American Board of Internal Medicine, 2012.
American Board of Internal Medicine, Medical Oncology, 2015.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Cancer treatment outcomes
Cancer treatment decision making
Genitourinary Malignancies

Selected Publications

Knollman H, Goodwin JL, Jain R, Wong YN, Plimack ER, Geynsiman DM: Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol 7(6): 312-30, Dec 2015.

Egleston BL, Pedraza O, Wong YN, Dunbrack RL Jr, Griffin CL, Ross EA, Beck JR.: Characteristics of clinical trials that require participants to be fluent in English. Clin Trials. 12(6): 618-26, Dec 2015.

Boland PM, Ruth K, Matro JM, Rainey KL, Fang CY, Wong YN, Daly MB, Hall MJ.: Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing. Clin Genet. 88(6): 565-72, Dec 2015.

Geynisman D, Wong YN: Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients? JAMA Oncology 17: 1-2, Dec 2015 Notes: Epub ahead of print.

Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER.: Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs. 33(5): 1040-7, Oct 2015.

Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL.: Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care. 53(9): e65-92, Sep 2015.

Hoffman-Centis J, Wong YN: Perioperative and maintenance therapy following first-line therapy as paradigms for drug discovery in urothelial carcinoma. Clin Genitourin Cancer 13(4): 302-8, August 2015.

Sweeney CJ, Chen Yu-Hui, Carducci M, Liu G, Jarrad DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 373(8): 737-46, Aug 2015.

Galsky MD, Pal SK, Chowdhury S, Harshman LC, J. CS, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, N. Vaishampayan UN, Recine F, Dominik B, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE.: Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 121(15): 2586-93, Aug 1 2015.

Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH.: Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. J Clin Oncol. 33(20): 2254-61, Jul 10 2015.

back to top
Last updated: 03/29/2016
The Trustees of the University of Pennsylvania